Childhood myasthenia: Clinical subtypes and practical management

Developmental Medicine and Child Neurology

Volumn 49, Issue 8, 2007, Pages 629-635

  Parr, Jeremy R ^a   Jayawant, S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETYLCHOLINESTERASE; AMPICILLIN; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EPHEDRINE; ERYTHROMYCIN; FLUOXETINE; GADOLINIUM; GENTAMICIN; GUANIDINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MORPHINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PLECTIN; PREDNISOLONE; PYRIDOSTIGMINE; QUINIDINE; RAPSYN; STEROID; TACROLIMUS; UNINDEXED DRUG;

CASE MANAGEMENT; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIPLOPIA; DISEASE CLASSIFICATION; DRUG MEGADOSE; EATON LAMBERT SYNDROME; HUMAN; MUSCLE WEAKNESS; MYASTHENIA; MYASTHENIA GRAVIS; MYASTHENIA LIKE SYNDROME; NEUROMUSCULAR JUNCTION DISORDER; OPHTHALMOPLEGIA; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PTOSIS; REVIEW; THYMECTOMY; WEAKNESS;

HUMANS; MYASTHENIA GRAVIS; PEDIATRICS; PRACTICE GUIDELINES;

EID: 34547431166     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2007.00629.x     Document Type: Review

References (56)

1. Andrews PI, Massey JM, Sanders DB. (1993) Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology 43: 977-982.
2. Vincent A. (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2: 797-804.
3. Garlepp MI, Dawkins RL, Christiansen FT. (1983) HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis. Br Med J (Clin Res Ed) 286: 1442-1443.
4. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. (1980) Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103: 579-601.
5. Toth C, McDonald D, Oger J, Brownell K. (2006) Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand 114: 124-132.
6. Oosterhuis HJ. (1989) The natural course of myasthenia gravis: A long term follow up study. J Neurol Neurosurg Psychiatry 52: 1121-1127.
7. Afifi AK, Bell WE. (1993) Tests for juvenile myasthenia gravis: comparative diagnostic yield and prediction of outcome. J Child Neurol 8: 403-411.
8. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J. (1997) Ocular myasthenia gravis: Response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62: 156-162.
9. Kupersmith MJ, Latkany R, Homel P. (2003) Development of generalised disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60: 243-248.
10. Vincent A, Palace J, Hilton-Jones D. (2001) Myasthenia gravis. Lancet 357: 2122-2128.
11. Kusner LL, Puwanant A, Kaminski HJ. (2006). Ocular myasthenia: diagnosis, treatment and pathogenesis. Neurologist 12: 231-239.
12. Sanders DB, Andrews I, Howard JF, Massey JM. (1997) Seronegative myasthenia gravis. Neurology 48: S40-45.
13. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368.
14. Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, Hilton-Jones D, Matthews PM, Vincent A. (2006) MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129: 1481-1492.
15. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, Vincent A, Saruhan-Direskeneli G. (2007) Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68: 609-611.
16. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IK, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge H W. (2006) Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 13: 691-699.
17. Tellez-Zenteno JF, Hernandez-Ronquillo L, Salinas V, Estanol B, Da Silva O. (2004) Myasthenia gravis and pregnancy: Clinical implications and neonatal outcome. BMC Musculoskelet Disord 5: 42.
18. Gardnerova M, Eymard B, Morel E, Faltin M, Zajac J, Sadovsky O, Tripon P, Domergue M, Vernet-der Garabedian B, Bach JF. (1997) The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn. Neurology 48: 50-54.
19. O'Neill JH, Murray NM, Newsom-Davis J. (1988) The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111: 577-596.
20. Maddison P, Lang B, Mills K, Newsom-Davis J. (2001) Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 70: 212-217.
21. Newsom-Davis J, Murray NM. (1984) Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34: 480-485.
22. Lambert EH, Eaton LM, Rooke ED. (1956) Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 187: 612-613.
23. Maddison P, Newsom-Davis J. (2005) Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 18: CD003279.
24. Middleton LT. (1996) Congenital myasthenic syndromes. 34th ENMC International Workshop, 10-11 June 1995. Neuromuscul Disord 6: 133-136.
25. Engel AG, Ohno K, Sine SM. (2003) Congenital myasthenic syndromes: progress over the past decade. Muscle Nerve 27: 4-25.
26. Beeson D, Hantai D, Lochmuller H, Engel AG. (2005) 126th International Workshop: Congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands. Neuromuscul Disord 15: 498-512.
27. Byring RF, Pihko H, Tsujino A, Shen XM, Gustafsson B, Hackman P, Ohno K, Engel AG, Udd B. (2002) Congenital myasthenic syndrome associated with episodic apnea and sudden infant death. Neuromuscul Disord 12: 548-553.
28. Barisic N, Muller JS, Paucic-Kirincic E, Gazdik M, Lah-Tomulic K, Pertl A, Sertic J, Zurak N, Lochmuller H, Abicht A. (2005) Clinical variability of CMS-EA (congenital myasthenic syndrome with episodic apnea) due to identical ChAT mutations in two infants. Eur J Paediatr Neurol 9: 7-12.
29. Ohno K, Tsujino A, Brengman JM, Harper CM, Bajzer Z, Udd B, Beyring R, Robb S, Kirkham FJ, Engel AG. (2001) Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A 98: 2017-2022.
30. Walls TJ, Engel AG, Nagel AS, Harper CM, Trastek VF. (1993) Congenital myasthenic syndrome associated with paucity of synaptic vesicles and reduced quantal release. Ann N Y Acad Sci 681: 461-468.
31. Maselli RA, Kong DZ, Bowe CM, McDonald CM, Ellis WG, Agius MA, Gomez CM, Richman DP, Wollmann RL. (2001) Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology 57: 279-289.
32. Milone M, Fukuda T, Shen XM, Tsujino A, Brengman J, Engel AG. (2006) Novel congenital myasthenic syndromes associated with defects in quantal release. Neurology 66: 1223-1229.
33. Bady B, Chauplannaz G, Carrier H. (1987) Congenital Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 50: 476-478.
34. Hutchinson DO, Walls TJ, Nakano S, Camp S, Taylor P, Harper CM, Groover RV, Peterson HA, Jamieson DG, Engel AG. (1993) Congenital endplate acetylcholinesterase deficiency. Brain 116: 633-653.
35. Shapira YA, Sadeh ME, Bergtraum MP, Tsujino A, Ohno K, Shen XM, Brengman J, Edwardson S, Matoth I, Engel AG. (2002) Three novel COLQ mutations and variation of phenotypic expressivity due to G240X. Neurology 58: 603-609.
36. Donger C, Krejci E, Serradell AP, Eymard B, Bon S, Nicole S, Chateau D, Gary F, Fardeau M, Massoulie J, Guicheney P. (1998) Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic). Am J Hum Genet 63: 967-975.
37. Bestue-Cardiel M, Saenz de Cabezon-Alvarez A, Capablo-Liesa JL, Lopez-Pison J, Pena-Segura JL, Martin-Martinez J, Engel AG. (2005) Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 65: 144-146.
38. Milone M, Wang HL, Ohno K, Fukudome T, Pruitt JN, Bren N, Sine SM, Engel AG. (1997) Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit. J Neurosci 17: 5651-5665.
39. Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN. (1982) A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 11: 553-569.
40. Burke G, Cossins J, Maxwell S, Robb S, Nicolle M, Vincent A, Newsom-Davis J, Palace J, Beeson D. (2004) Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscul Disord 14: 356-364.
41. Burke G, Cossins J, Maxwell S, Owens G, Vincent A, Robb S, Nicolle M, Hilton-Jones D, Newsom-Davis J, Palace J, Beeson D. (2003) Rapsyn mutations in hereditary myasthenia: Distinct early- and late-onset phenotypes. Neurology 61: 826-828.
42. Ohno K, Engel AG, Shen XM, Selcen D, Brengman J, Harper CM, Tsujino A, Milone M. (2002) Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am J Hum Genet 70: 875-885.
43. Chevessier F, Faraut B, Ravel-Chapuis A, Richard P, Gaudon K, Bauche S, Prioleau C, Herbst R, Goillot E, Ioos C, et al. (2004) MuSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet 13: 3229-3240.
44. Tsujino A, Maertens C, Ohno K, Shen XM, Fukuda T, Harper CM, Cannon SC, Engel AG. (2003) Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc Natl Acad Sci U S A 100: 7377-7382.
45. Banwell BL, Russel J, Fukudome T, Shen XM, Stilling G, Engel AG. (1999) Myopathy, myasthenic syndrome, and epidermolysis bullosa simplex due to plectin deficiency. J Neuropathol Exp Neurol 58: 832-846.
46. Beeson D, Higuchi O, Palace J, Cossins J, Spearman H, Maxwell S, Newsom-Davis J, Burke G, Fawcett P, Motomura M, et al. (2006) Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 313: 1975-1978.
47. Rodolico C, Toscano A, Autunno M, Messina S, Nicolosi C, Aguennouz M, Laura M, Girlanda P, Messina C, Vita G. (2002) Limb-girdle myasthenia: clinical, electrophysiological and morphological features in familial and autoimmune cases. Neuromuscul Disord 12: 964-969.
48. Slater CR, Fawcett PR, Walls TJ, Lyons PR, Bailey SJ, Beeson D, Young C, Gardner-Medwin D. (2006) Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. Brain 129: 2061-2076.
49. Oh SJ, Kuruoglu R. (1992) Chronic limb-girdle myasthenia gravis. Neurology 42: 1153-1156.
50. Vincent A, Newland C, Brueton L, Beeson D, Riemersma S, Huson SM, Newsom-Davis J. (1995) Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 346: 24-25.
51. Hoffman K, Muller JS, Stricker S, Megarbane A, Rajab A, Linder TH, Cohen M, Chouery E, Adaimy L, Ghanem I, et al. (2006) Escobar syndrome is a prenatal myasthenia caused by disruption of the acetycholine receptor fetal gamma subunit. Am J Hum Genet 79: 303-312.
52. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. (2005) Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity. Neurology 64: 1968-1970.
53. Zielonka T, Kostera-Pruszczyk A, Ryniewicz B, Korczynski P, Szyluk B. (2006) How accurate is spirometry at predicting restrictive pulmonary impairment in children with myasthenia gravis. J Physiol Pharmacol 57 (Suppl 4): 409-416.
54. Harper CM, Fukodome T, Engel AG. (2003) Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 60: 1710-1713.
55. Colomer J, Muller JS, Vernet A, Nascimento A, Pons M, Gonzalez V, Abicht A, Lochmuller H. (2006) Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine. Neuromuscul Disord 16: 329-333.
56. Anlar B, Varli K, Ozdirim E, Ertan M. (1996) 3,4-diaminopyridine in childhood myasthenia: Double-blind, placebo-controlled trial. J Child Neurol 11: 458-461.